Category: Money tips Release Date: 2006-11-11
Source: Guangdong Lark Letter Author: Wu Xun
Good performance is expected to support the stock price. As in 10-25 results announcement released on time, one company's shares out of a magnificent rally. We know from the theory of stock valuation, stock performance, growth is endogenous rise in power. In the first three quarters, the company main business income of 26,481 million, more than in the first half-year increase of 25.99%, main business profit of 129.38 thousand yuan more than in the first half-year increase of 44%, net profit of 46.71 thousand yuan, compared with the previous half-year increase of 154.97%. Recombinant human insulin products export reached 4.67 million yuan. From this level, we can glimpse the company rose early motivation.
Quality assets to enhance value. With 06-11-21 day's closing price, the company book value of 1.94. Company's main products and promising recombinant human insulin powder and freeze-dried injection, the town of the brain capsule, soft bag infusion products. Among them, recombinant human insulin powder and freeze-dried injection, gross profit margins in the town of the brain capsule has reached more than 68%. Buy stocks is to look at buying the company's assets, the company has investment value.
Market rumors caused by lower stock prices. When the positive digested by the market to begin after the test a low stock price adjustment, Tonghua Dongbao (600,867) also can not run away this curse knot? From the disk point of view, that the company announced three quarterly on the 25th day onwards, 26 as well as the subsequent decline to stabilize until after the November 3 strength began to test a low price, many of them to do the main dish in sight. So, Tonghua Dongbao will test a low sustained long do? We believe that the recent decline in stock prices quoted on the economy and medicine Tonghua Dongbao challenged on the export of data. In fact, the company disclosed in the three quarterly export data and Customs export data are basically consistent. It is at this point, the main means of its power and its Road, by suppressing bad rumors price.
Fist products provide room for imagination. The company's leading products of recombinant human insulin-steady growth in exports, while domestic insulin formulations sales are up significantly. We believe that the market will re-examine the company's insulin products, the value of speculation in the market digested the bad element will regain an upward trend.
Company's stock price to start at the beginning, after quite a long period of sideways can be described as the main intervention is not shallow. After three weeks of trading day of the test a low order, which is trading close to their stock price starts high of 6.88 second. Expected stock price will face a turning point involved, from the "long-term tracking, band and out" policy considerations, should arouse our attention!
